Skip to main content
Premium Trial:

Request an Annual Quote

Genome Institute of Singapore to Use Geneticxchange Middleware

NEW YORK, Jan. 25 - Singapore's flagship genomics institute plans to use Geneticxchange's middleware platform as its core infrastructure for biological research, the company said on Wednesday.


That platform, the K1 Data Integration Middleware Platform System, is designed to collect and integrate multidimensional biological data. The platform is specially constructed for bioinformaticists and genomic researchers and, according to Menlo Park, Calif.-based Geneticxchange, allows users to design their own modifications and improvements to the system.


The Genome Institute of Singapore will use this system to develop its research programs in functional genomics. That program, launched in 2000 as the cornerstone of a $3 billion Singaporean biomedical sciences initiative, is lead by Edison Liu, formerly scientific director of the division of clinical sciences at the National Cancer Institute.


Liu told GenomeWeb in early 2001 that the institute, which will partner with local companies and institutes to commercialize new findings, would focus on molecular epidemiology, pharmacogenomics, comparative genomics, and cell biology.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.